Brief: BeyondSpring Presents Phase 1 Data On Anti-Cancer Effect Of Plinabulin In Combination With Checkpoint Inhibitors In SCLC At The American Society Of Clinical Oncology Annual Meeting
24/05/2021 13:10
May 24 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING PRESENTS PHASE 1 DATA ON THE ANTI-CANCER
EFFECT OF
PLINABULIN IN COMBINATION WITH CHECKPOINT INHIBITORS IN SCLC AT
THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
* BEYONDSPRING INC - PLINABULIN, IN COMBINATION WITH
NIVOLUMAB AND
IPILIMUMAB, SHOWS 46% OBJECTIVE RESPONSE RATE (ORR) IN 13
EVALUABLE PATIENTS
* BEYONDSPRING INC - PLINABULIN COMBINATION WAS ABLE TO
RE-SENSITIZE TUMORS THAT HAD PROGRESSED ON PRIOR PD-1/PD-L1
INHIBITORS WITH 43% ORR
Source text for Eikon: ID:nGNX3PBJnV
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value